戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ss estimates except for being antiretroviral therapy naive.
2  at least 2 years or were enzyme replacement therapy-naive.
3 bavirin (null responders), and 32 (39%) were therapy naive; 39 (48%) were African American.
4 bel, non-inferiority trial in antiretroviral-therapy-naive adults (age >/=18 years) with documented H
5 label study in HIV-1-infected antiretroviral therapy-naive adults (CD4+ >=50 cells/mm3).
6 riority study, HIV-1-infected antiretroviral therapy-naive adults with HIV-1 RNA concentration of 100
7 estrant and Anastrozole Compared in Hormonal Therapy Naive Advanced Breast Cancer) trial.
8                         Forty antiretroviral-therapy-naive, age- and CD4-matched women and men were t
9 hibition increases CDK4i/6i efficacy against therapy naive and CDK4i/6i-resistant AM cells in xenogra
10                               Antiretroviral therapy-naive and AIDS-free individuals were followed fr
11  detected in lymph nodes from antiretroviral therapy-naive and antiretroviral therapy-suppressed peop
12 roves progression-free survival in endocrine therapy-naive and endocrine therapy-resistant metastatic
13 o lopinavir-ritonavir in both antiretroviral therapy-naive and protease inhibitor-experienced patient
14 encies might be a promising strategy to kill therapy-naive and treatment-resistant OXPHOS-reliant LSC
15  infected individuals who are antiretroviral therapy naive as well as in those who are receiving high
16 -infected individuals who are antiretroviral therapy-naive as well as those who are receiving highly
17  with undetectable virus levels (TxHIV), and therapy-naive aviremic elite controllers (EC).
18                                 Methods: Ten therapy-naive, biopsy-confirmed PCa patients planned for
19 rdiac structure and function are affected by therapy-naive cancer.
20                 Following protease inhibitor therapy, naive CD4+ T cells increased only if they were
21 s in a cross-sectional cohort of 815 Italian therapy-naive CHC patients.
22 led a heterogeneous cohort of antiretroviral therapy-naive children (age, 3 months to 18 years); pati
23 cell counts remained stable over 24 weeks in therapy-naive children and decrease slightly in previous
24      CD4 counts in perinatally HIV-infected, therapy-naive children in the Paediatric European Networ
25  We evaluated plasma from 212 antiretroviral therapy-naive children with HIV (1-3 years old).
26 was to assess the activity of vinblastine in therapy-naive children.
27          Simian-HIV infection of 11 pairs of therapy-naive dams and infant rhesus macaques for 24 mon
28              445 patients were admitted with therapy-naive disease of the knee and were primarily tre
29 ts infected with HIV who were antiretroviral therapy-naive during the observation period.
30 inical progress is hampered by a shortage of therapy-naive ER(+) tumor models that recapitulate metas
31 hat NSG-Pro mice facilitate establishment of therapy-naive, estrogen-dependent PDX tumors that progre
32 ting CRF02_A/G-IbNG-infected, antiretroviral therapy-naive female commercial sex workers in Dakar, Se
33      Fifteen renal allograft recipients with therapy-naive HCV genotype (GT) 1a, 1b, or 4 were treate
34 responses in 23 highly active antiretroviral therapy naive HIV-infected patients.
35                               Antiretroviral therapy-naive HIV-1 infected infants experience poor vir
36 s in peripheral blood samples from groups of therapy-naive HIV-1-infected (n = 21) and HIV-2-infected
37 t memory subpopulations in 20 antiretroviral therapy-naive HIV-1-infected individuals at approximatel
38 d that hnRNPA0 levels in PBMCs were lower in therapy-naive HIV-1-infected individuals compared to hea
39 in HIV-1 target cells and lower expressed in therapy-naive HIV-1-infected individuals.
40                                              Therapy-naive HIV-1-infected patients without baseline r
41 ellular fractions of semen from 74 antiviral therapy-naive HIV-1-seropositive men and 53 paired blood
42 ations (DRM), including among antiretroviral therapy-naive HIV-infected individuals.
43 from 36 HIV-uninfected and 30 antiretroviral therapy-naive HIV-infected men without known CV risk fac
44 omography in 35 asymptomatic, antiretroviral-therapy-naive, HIV-1-infected adults with latent tubercu
45 n-label, multicenter study in antiretroviral therapy-naive, HIV-1-infected adults.
46 vudine and lamivudine, in 653 antiretroviral therapy-naive human immunodeficiency virus (HIV) type 1-
47              A5202 randomized antiretroviral therapy-naive human immunodeficiency virus-infected subj
48 e of the genital origin of HIV in semen from therapy naive individuals and men receiving suppressive
49 ve, M. tuberculosis infected, antiretroviral therapy naive individuals following completion of preven
50 tis C virus (HCV)-coinfected, antiretroviral therapy-naive individuals before, during, and after pegy
51 enter study, 208 women with newly diagnosed, therapy-naive invasive breast cancer were enrolled in ac
52  including 15 HIV-1-infected, antiretroviral therapy-naive men starting once-daily treatment with DTG
53 agent daratumumab sensitivity in vulnerable, therapy naive MM patients.
54 roof-of-concept study, we supplemented PA to therapy-naive MS patients and as an add-on to MS immunot
55 Dynamic (18)F-FDG PET/CT was performed on 20 therapy-naive NSCLC patients for whom primary surgical r
56 stricted collateral sensitivities, absent in therapy naive or fully resistant cells, suggesting the p
57 nsition]) were evaluated in 66 human primary therapy-naive OSCCs.
58  (SNPs) to viral load (VL) in antiretroviral therapy-naive participants (n = 2440) with varying demog
59 itudinal blood samples of recently infected, therapy-naive participants were interrogated with UDS.
60                            In 235 biological therapy-naive participants who had 10 or more measures i
61 ssected 678 HGSOC transcriptomes of systemic therapy naive patients-sourced from public repositories-
62                                              Therapy-naive patients (n = 14,700) were followed from e
63 from separate melanoma cohorts including 345 therapy-naive patients and 35 patients with patient-matc
64 blind, comparative trial, 653 antiretroviral therapy-naive patients received lopinavir/ritonavir or n
65 udy using plasma HIV RNA from antiretroviral therapy-naive patients reported that 14 naturally occurr
66 hock protein (HSP) receptor, was observed in therapy-naive patients who had no evidence of ongoing vi
67 e antiretroviral therapy (HAART), but not in therapy-naive patients who had substantial levels of pla
68 on, we evaluated HIV-positive antiretroviral therapy-naive patients who were on lithium therapy.
69                    All consecutive, systemic therapy-naive patients with ATC with active disease and
70 ted interferon alfa-2a versus hydroxyurea in therapy-naive patients with either high-risk essential t
71 nd September 2019 and included 122 radiation therapy-naive patients with OOPC treated with PRT.
72 ples from castration-resistant compared with therapy-naive patients.
73 ential therapeutic option for antiretroviral-therapy-naive patients.
74 cell BCMA expression was present in all BCMA therapy-naive patients.
75  AC after radiotherapy failure than those in therapy-naive PCa, prostatic intraepithelial neoplasia,
76 d 2018, 1119 newly and previously diagnosed, therapy-naive persons with HIV (PWH) from San Diego were
77 ars old with unresectable and/or progressive therapy-naive PLGG were eligible.
78 e to restoration to health in antiretroviral therapy-naive PLWH, which is compounded by the rising ra
79  following characteristics, especially among therapy-naive potential source partners: seminal cytomeg
80 750 tumors of diverse origin, including >150 therapy-naive, primary, and recurrent SCCHNs.
81 tation in colon biopsies from antiretroviral therapy-naive PWH versus controls.
82 sion of ANXA1 and cytokines were assessed in therapy-naive rhesus macaques during early and chronic s
83 esults indicate HIV-positive, antiretroviral therapy-naive South-African blacks with two APOL1 risk a
84  recurrent SCCHN compared to patient-matched therapy naive specimens.
85 V suppression was seen in the antiretroviral-therapy-naive study participants with viraemia carrying
86 s of CXCL13 in HIV-1-infected antiretroviral therapy-naive subjects correlated with viral load and we
87  their recurrence in low-mutation burden and therapy naive tumors.
88 pling of transcriptional programs present in therapy naive tumors.
89 ons and deletions enriched in autopsy versus therapy-naive tumors.
90    Out of 12 urine samples from independent, therapy-naive WD patients, 9 were positive for T. whippl
91 table by PCR in the urine of the majority of therapy-naive WD patients.
92             Eligible patients were endocrine therapy-naive, with WHO performance status 0-2, and at l
93 rogression and survival in an antiretroviral therapy-naive Zimbabwean cohort (n = 312).